|Other Names||Collagen alpha-1(XXV) chain, Alzheimer disease amyloid-associated protein, AMY, CLAC-P, Collagen-like Alzheimer amyloid plaque component, CLAC, COL25A1 (HGNC:18603)|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6964a was selected from the N-term region of human COL25A1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibits fibrillization of beta amyloid peptide during the elongation phase. Has also been shown to assemble amyloid fibrils into protease-resistant aggregates. Binds heparin.|
|Cellular Location||Membrane; Single-pass type II membrane protein. Note=After proteolytic cleavage, CLAC is secreted|
|Tissue Location||Expressed predominantly in brain. Deposited preferentially in primitive or neuritic amyloid plaques which are typical of Alzheimer disease.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
COL25A1 is a brain-specific membrane-bound collagen. Proteolytic processing releases CLAC, a soluble form of COL25A1 containing the extracellular collagen domains that associates with senile plaques in Alzheimer disease.
Kakuyama,H., et.al., Biochemistry 44 (47), 15602-15609 (2005)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.